Used as a chiral intermediate in the synthesis of pharmaceutical agents, particularly in the development of central nervous system (CNS) active compounds. Its structure supports high enantioselectivity, making it valuable in asymmetric synthesis for drug candidates targeting neurological disorders. The compound’s trifluoromethyl and naphthyl groups enhance binding affinity and metabolic stability, which are beneficial in optimizing pharmacokinetic properties. It is also employed in research settings to develop novel receptor modulators, including those acting on serotonin and dopamine pathways.